Solutions to TCTMD’s 2022 Cardiology Crossword Challenge
If a few missing clues were keeping you up at night, start plumping your pillow.
Thank you to everyone who spent some of the last days of 2022 trying to crack what proved to be a very tricky puzzle! We are reaching out to the prizewinning entries for this year’s Cardiology Crossword Challenge and will also be rewarding a few of the brave souls who kept the conversation alive on Twitter with Platinum memberships on TCTMD.
As you’ve hopefully noticed, we’ve actually been rolling out the solutions in batches, based on subspecialty, recapping the top news according to topic: General Cardiology & Prevention, Coronary, Structural, Endovascular, Heart Failure, Heart Rhythm, and Policy & Practice.
Thanks for playing along. If you have any comments/complaints on this year’s puzzle, let us know
|
Across |
|
1. Sows new hope for end-stage HF? |
|
6. No better than watch and wait in CS |
|
8. Overturned with 32 Down, roiling cardio-obstetrics |
|
9. Rare but real, esp. for males age 18-29 yrs (3,11) |
|
15. Big heart hoax of pandemic's 2nd yr (7,3) |
|
17. The new not quite normal |
|
20. Once weekly jab may make obesity SURMOUNTable |
|
21. Key diagnostic, planning tool in AR |
|
22. Option FDA grants Watchman FLX |
|
23. Best biomarker for chest pain eval. |
|
24. Rapid uptitration pays off in acute HF |
|
25. Big backfire for rivaroxaban in rheumatic HD |
|
27. AI data essentials |
|
30. 5 Down competitor greenlit by FDA |
|
31. Trial makes good on HFpEF promise? |
|
33. Injectable class of 41 Across |
|
34. TAVI or surgery |
|
35. Seven simply doesn't cut it in 2022, says AHA (9,5) |
|
38. Plays key role in cutting symptom-to-balloon time |
|
41. May herald sea change for Lp(a)? (5,1,4) |
|
43. Trial a bright spot for PE? |
|
44. New combo subspec. gets new ESC guidance |
|
46. A wake-up call, first for TAVI, now TEER? (9,8) |
|
48. Cuts lead-related complications (4,3) |
|
51. Verily, he of 40 Down (6,6) |
|
52. Akin to Kawasaki, after SARS-CoV-2 in kids |
|
53. It's too high in 20 Across |
|
54. 2022's variola, but myocarditis rare (6,3) |
|
56. PAD subtype alleviated in 49 Down |
|
57. Rare clot risk with adenovirus-based COVID jab |
|
59. Many went 'missing' during COVID-19 lockdowns |
|
60. With 26 Down, contender in long-running LM debate |
|
61. Abandoned drug class candidate comes up ROSEs |
|
65. David of first attempt for 1 Across |
|
66. Promising new target for anticoagulation |
|
Down |
|
1. Brand name DOAC may help with radial artery occlusion |
|
2. Perc of a big birthday? (4,5,6) |
|
3. Some saw spin, some success in Sentinel showdown (9,4) |
|
4. USPSTF says not to use in prim. prev. |
|
5. Novel cardiac myosin inhibitor helps the large-hearted |
|
7. Disease target for 5 Down |
|
10. Of morbidly diseased organs or plaque-filled arteries |
|
11. So far, it's a death match for famed NHLBI trial (8,6) |
|
12. More AEDs, ablation; less ICDs since ESC's 2015 ed. (2,3,9) |
|
13. Fellow supports tighter BP control in pregnancy? |
|
14. Noninvasive functional/anatomical test |
|
16. 1st approved SGLT2i for HFpEF |
|
18. May yield better long-term survival than bioprosthetic AVR |
|
19. Scrambled vacation correspondence sees RAPID effect on SVT? |
|
26. With 60 Across, contender in long-running LM debate |
|
28. 5-yr data should have an IN.PACT |
|
29. FDA plans ban as industry makes a mint? |
|
32. Overturned with 8 Across, roiling cardio-obstetrics |
|
36. How to cure gut worms that have COVID |
|
37. Option might outpace BiV CRT |
|
39. Animal, vegetable, placebo? (7,3) |
|
40. Cardiologist returns to top FDA spot? |
|
42. Part of a circle that meets to standardize definitions? |
|
45. Pricey therapy faced rocky rollout after late 2021 approval |
|
47. Trial locks down polypill in secondary prevention? |
|
48. Peak trial comparing mitral repair vs replacement |
|
49. In long-awaited PAD trial, surgery not worst |
|
50. In short supply for much of 2022 |
|
51. STICH, refreshed, no prize for PCI? |
|
55. New SCAI guidelines fill a hole? |
|
58. Got new guidelines after 12 years of watchful waiting |
|
62. Repletion might help in HF |
|
63. Alternativ. to 37 Down |
|
64. Fracture might help, but might harm |
|
|
Shelley Wood is Managing Editor of TCTMD and the Editorial Director at CRF. She did her undergraduate degree at McGill…
Read Full Bio
Comments